E-mail: greslik@med.muni.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- ANALYSIS OF CHROMOSOMAL ABNORMALITIES ASSOCIATED WITH HIGHER RISK OF MALIGNANT TRANSFORMATION OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE
- ASSOCIATION BETWEEN CHROMOSOMAL CHANGES AND STANDARD PROGNOSTIC FACTORS IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
- ASSOCIATION OF PLASMA CELL PHENOTYPE WITH CYTOGENETIC FINDINGS IN MULTIPLE MYELOMA
- Association Study of Ploidy Category with Mitotic Disruption In Multiple Myeloma
- CENTROSOME AMPLIFICATION AS A POSSIBLE MARKER OF MYELOMA CELL PRECURSORS
- CLINICAL IMPLICATION OF CENTROSOME AMPLIFICATION AND EXPRESSION OF CENTROSOMAL FUNCTIONAL GENES IN MM
- COMPARISON OF PROGNOSTIC IMPACT OF CHROMOSOME 1Q21 GAIN IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY VELCADE, THALIDOMIDE AND ANY CONVENTIONAL THERAPY
- CULATING MICRORNA AS POTENTIAL BIOMARKERS OF MGUS AND MM
- Extramedullary Relapse of Multiple Myeloma - Plasma Cells Characteristics
- Gain(1)(q21) Defines Group of Newly Diagnosed Multiple Myeloma Patients with Poor Prognosis
- GAIN/AMPLIFICATION OF 1Q21 IS THE MOST POWERFUL GENETIC PROGNOSTIC FACTOR FOR PATIENTS TREATED BY AUTOLOGOUS STEM CELL TRANSPLANTATION
- Genome Wide Profiling Of Chromosomal Abnormalities In 37 Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS)
- HIGH LEVELS OF NEURAL STEM CELL MARKER NESTIN ARE ASSOCIATED WITH 1Q21 GAIN AND PREDICT WORSE RESPONSE TO CONVENTIONAL AND NOVEL THERAPY IN MULTIPLE MYELOMA
- Incidence of Centrosome Amplification in Multiple Myeloma
- Kompenzují nové léky vliv cytogenetických negativních prognostických markerů u pacientů s mnohočetným myelomem? Aktualizované výsledky o rok později.
- NEURAL STEM CELL MARKER NESTIN AS A POTENTIAL UNFAVORABLE FACTOR FOR MULTIPLE MYELOMA
- Newly Diagnosed Multiple Myeloma Patients with 1q21 Amplification Treated by Autologous Stem Cell Transplantation Have Shorter Progression-Free Survival Interval.
- Occurrence of Chromosomal Abnormalities In Bone Marrow CD14+ monocytes of Multiple Myeloma Patients
- THE POOR PROGNOSIS ASSOCIATED WITH GAIN/AMPLIFICATION OF 1Q21 IN RELAPSED MULTIPLE MYELOMA PATIENTS MAY BE OVERCOME BY VELCADE BASED REGIMEN IN CONTRARY OF THALIDOMIDE BASED REGIMEN
